Longterm beneficial effect of canakinumab in colchicine-resistant familial mediterranean fever

Journal of Rheumatology

Volumn 44, Issue 1, 2017, Pages 102-109

  Laskari, Katerina ^a   Boura, Panagiota ^b   Dalekos, George N ^c   Garyfallos, Alexandros ^b   Karokis, Dimitrios ^d   Pikazis, Dimitrios ^a   Settas, Loukas ^b   Skarantavos, Grigoris ^a   Tsitsami, Elena ^a   Sfikakis, Petros P ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF THESSALY   (Greece)

^d Private rheumatologist   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANAKINRA; AZATHIOPRINE; CANAKINUMAB; COLCHICINE; CORTICOSTEROID DERIVATIVE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; ANTIINFLAMMATORY AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DISEASE REGISTRY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILIAL MEDITERRANEAN FEVER; FEMALE; FOLLOW UP; GREECE; HUMAN; LABORATORY TEST; LEUKOPENIA; LONGITUDINAL STUDY; MALE; MONOTHERAPY; MYALGIA; OFF LABEL DRUG USE; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT RESPONSE; URINARY TRACT INFECTION; VIRAL GASTROENTERITIS; MIDDLE AGED; RETREATMENT; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLCHICINE; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; OFF-LABEL USE; REMISSION INDUCTION; RETREATMENT; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85008240326     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.160518     Document Type: Article

References (27)

1. Migita K, Izumi Y, Fujikawa K, Agematsu K, Masumoto J, Jiuchi Y, et al. Dysregulated mature IL-1β production in familial Mediterranean fever. Rheumatology 2015;54:660-5.
2. Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 2013;25:469-84.
3. Turgay S, Aksu K, Dokuyucu O, Ertenli A, Gul A, Karaaslan Y, et al. Epidemiology of colchicine resistant Familial Mediterranean fever disease (CrFMF) in Turkey. Pediatr Rheumatol 2015;13 Suppl:P90.
4. Soriano A, Verecchia E, Afeltra A, Landolfi R, Manna R. IL-1β biological treatment of familial Mediterranean fever. Clin Rev Allergy Immunol 2013;45:117-30.
5. Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997;40:1879-85.
6. Giancane G, Ter Haar NM, Wulffraat N, Vastert SJ, Barron K, Hentgen V, et al. Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Ann Rheum Dis 2015;74:635-41.
7. Shinar Y, Obici L, Aksentijevich I, Bennetts B, Austrup F, Ceccherini I, et al; European Molecular Genetics Quality Network. Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis 2012;71:1599-605.
8. Ozen S, Demirkaya E, Duzova A, Erdogan O, Erken E, Gul A, et al; FMF Arthritis Vasculitis and Orphan disease Research in pediatric rheumatology (FAVOR) and Turkish FMF study group. FMF50: A score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis 2014;73:897-901.
9. Karatsourakis TP, Oikonomaki KN, Tzioufas AG, Moutsopoulos HM. Periodic fevers in adult Greeks: Clinical and molecular presentation. Clin Exp Rheumatol 2014;32 Suppl 84:S45-8.
10. Kilinc M, Ganiyusufoglu E, Sager H, Celik A, Olgar S, Cetin GY, et al. The report of sequence analysis on familial Mediterranean fever gene (MEFV) in South-eastern Mediterranean region (Kahramanmaraş) of Turkey. Rheumatol Int 2016;36:25-31.
11. Eroglu FK, Beşbaş N, Topaloglu R, Ozen S. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents. Rheumatol Int 2015;35:1733-7.
12. Mitroulis I, Skendros P, Oikonomou A, Tzioufas AG, Ritis K. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. Ann Rheum Dis 2011;70:1347-8.
13. Alpa M, Roccatello D. Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment. Drug Des Devel Ther 2015;9:1983-7.
14. Hacihamdioglu DO, Ozen S. Canakinumab induces remission in a patient with resistant familial Mediterranean fever. Rheumatology 2012;51:1041.
15. Gul A, Ozdogan H, Erer B, Ugurlu S, Kasapcopur O, Davis N, et al. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther 2015;17:243.
16. Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L, et al; MAIL1 (Maladies Auto-inflammatoires et Anti-IL-1) study Group on behalf of CRI (Club Rhumatisme et Inflammation). Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: A nationwide survey. Orphanet J Rare Dis 2015;10:19.
17. Cetin P, Sari I, Sozeri B, Cam O, Birlik M, Akkoc N, et al. Efficacy of interleukin-1 targeting treatments in patients with familial Mediterranean fever. Inflammation 2015;38:27-31.
18. Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Kone-Paut I. Interleukin-1 targeting drugs in familial Mediterranean fever: A case series and a review of the literature. Semin Arthritis Rheum 2011;41:265-71.
19. Ozcakar ZB, Ozdel S, Yilmaz S, Kurt-Şukur ED, Ekim M, Yalcinkaya F. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol 2016;35:441-6.
20. Başaran O, Uncu N, Celikel BA, Taktak A, Gur G, Cakar N. Interleukin-1 targeting treatment in familial Mediterranean fever: An experience of pediatric patients. Mod Rheumatol 2015;25:621-4.
21. Brik R, Butbul-Aviel Y, Lubin S, Ben Dayan E, Rachmilewitz-Minei T, Tseng L, et al. Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: A 6-month open-label, single-arm pilot study. Arthritis Rheumatol 2014;66:3241-3.
22. Hentgen V, Grateau G, Kone-Paut I, Livneh A, Padeh S, Rozenbaum M, et al. Evidence-based recommendations for the practical management of familial Mediterranean fever. Semin Arthritis Rheum 2013;43:387-91.
23. Moser C, Pohl G, Haslinger I, Knapp S, Rowczenio D, Russel T, et al. Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. Nephrol Dial Transplant 2009;24:676-8.
24. Stankovic Stojanovic K, Delmas Y, Torres PU, Peltier J, Pelle G, Jeru I, et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant 2012;27:1898-901.
25. Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 2007;66:1545-6.
26. Omenetti A, Carta S, Delfino L, Martini A, Gattorno M, Rubartelli A. Increased NLRP3-dependent interleukin 1β secretion in patients with familial Mediterranean fever: Correlation with MEFV genotype. Ann Rheum Dis 2014;73:462-9.
27. Lidar M, Yonath H, Shechter N, Sikron F, Sadetzki S, Langevitz P, et al. Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev 2012;12:72-6.